Troubled by a clinical hold for another program, Advaxis now regains all rights to ADXS-NEO, a personalized immunotherapy in Phase I for cervical and head-and-neck cancers.

OvaScience’s cash plus a $49.5m venture capital raise leave Millendo with more than enough to get two current programs to data readouts in early 2020, company says. AMAG merges with Perosphere, adding to its hematology business.

The Japanese pharmaceutical companies will work with the Global Antibiotic Research and Development Partnership on screening targets for utility against WHO-listed priority pathogens. Avacta and LG Chem collaborate around the former’s Affimer technology.

Eli Lilly signed a licensing deal to develop a tau aggregation inhibitor small molecule for Alzheimer's disease – a drug that works differently from existing antibodies and could offer potential in combination regimens. AC Immune CEO Andrea Pfeifer talked to Scrip about the deal.

Silence will receive a small royalty on future sales of Alnylam’s Onpattro in Europe, and Alnylam is free to use Silence IP in other products.

Public Company Edition: Moderna's $604m IPO launches as the US stock market is in decline and public biotechs are doing especially poorly. Also, as Shire acquisition closing moves near, Takeda firms up additional financing; and Global Blood, Theravance, Amarin capitalize on good news.

The international biopharma industry is backing the UK life sciences sector, with UCB spearheading the charge with a £1bn commitment to R&D in the nation still in a state of flux regarding its exit from the European Union in 2019.

Following last December’s partnership in CNS with Autifony, BI undertakes a screening collaboration with Domain. Leo maintains its busy deal-making pace, partnering in dermatology with Evotec.

The company, which makes generic opioid products and the controversial Acthar Gel, is looking to chart a new course for the future – or make that two new courses.